A Randomized, Sham-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Intrathecal OAV101 in Type 2 Spinal Muscular Atrophy (SMA) Patients Who Are ≥ 2 to < 18 Years of Age, Treatment Naive, Sitting, and Never Ambulatory
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Onasemnogene-abeparvovec (Primary) ; Prednisolone sodium phosphate
- Indications Spinal muscular atrophy
- Focus Registrational; Therapeutic Use
- Acronyms STEER
- Sponsors Novartis Gene Therapies; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 20 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2024 This trial has been completed in Greece according to European Clinical Trials Database record.
- 16 Jan 2024 Status changed from active, no longer recruiting to recruiting.